PF-184

• UNSPSC Description:

  PF-184 is a potent and selective IKK-2 inhibitor (IC50: 37 nM) over rhIKK-1, IKKi, and more than 30 tyrosine and serine/threonine kinases. PF-184 can be used in the research of inflammation, such as asthma and chronic obstructive pulmonary disease[1].

• Target Antigen:

  IKK

• Type:

  Reference compound

• Related Pathways:

  NF-κB

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/pf-184-1.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(C1=NN(C2=C1CCC3=C2C=C(NC(C4=CC(N5C[C@](CO)([C@](CO)(C5)C)C)=NC=C4Cl)=O)C=C3)C6=CC=C(C=C6)F)N

• Molecular Weight:

  619.09

• References & Citations:

  [1]Cynthia D Sommers, et al. Novel tight-binding inhibitory factor-kappaB kinase (IKK-2) inhibitors demonstrate target-specific anti-inflammatory activities in cellular assays and following oral and local delivery in an in vivo model of airway inflammation. J Pharmacol Exp Ther. 2009 Aug;330(2):377-88.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported